Cowen on Intellia Therapeutics (NTLA): 'We continue to view NTLA as a leader in the gene editing space'
Cowen analyst Joseph Thome reiterated an Outperform rating and {REMOVEPT} price target on Intellia Therapeutics (NASDAQ: NTLA)The analyst comments "NTLA ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)